Session XXII: Colorectal Cancer: Metastatic Disease

Presentation during WCGIC:

All abstracts will be published on the Annals of Oncology website on Saturday, 02 July at 16:30 CEST.

Abstract titles and summaries were obtained from the ESMO WCGIC website; abstracts were translated, edited, and summarized in German.

------------------------------------------------------------------------------------------------------------------------------------------

O-6: Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients:

results of the phase III randomized TRIPLETE study by GONO

Summary in German follows soon on Saturday, July 2, 2022, after 11AM

 

------------------------------------------------------------------------------------------------------------------------------------------

O-7: Evidence of therapeutic effectiveness of III line cetuximab rechallenge in appropriately selected patients: finding from long-term follow-up of CRICKET and CAVE trials

Summary in German follows soon on Saturday, July 2, 2022, after 11AM

 

------------------------------------------------------------------------------------------------------------------------------------------

SO-37: Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib + cetuximab ± binimetinib:

subanalysis of BEACON CRC

Summary in German follows soon on Saturday, July 2, 2022, after 11AM

 

------------------------------------------------------------------------------------------------------------------------------------------

SO-38: Clinical efficacy and single cell analysis of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients

Summary in German follows soon on Saturday, July 2, 2022, after 11AM

 

------------------------------------------------------------------------------------------------------------------------------------------

O-8: Association of MSS/MSI-RNF43 molecular subtypes and clinical outcome of metastatic BRAF-V600E colorectal cancer patients treated with anti-BRAF/EGFR ± combinatorial therapies

Summary in German follows soon on Saturday, July 2, 2022, after 11AM

 

------------------------------------------------------------------------------------------------------------------------------------------

LBA-2: MOUNTAINEER: Open-label, phase 2 study of tucatinib in combination with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017)

Summary in German follows soon on Saturday, July 2, 2022, after 11AM

 

------------------------------------------------------------------------------------------------------------------------------------------

SO-39: Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100

Summary in German follows soon on Saturday, July 2, 2022, after 11AM

 

------------------------------------------------------------------------------------------------------------------------------------------

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Gesundheitsorganisationen (z.B. Universitätsspital, Swiss Academy of Multidisciplinary Oncology SAMO), Stiftungen (z.B. SONK St.Gallen Oncology Conferences) beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weiter erhält Oncoletter nicht an inhaltliche Bedingungen geknüpfte Unterstützung von Firmen zur Berichterstattung. Seit der Inbetriebnahme von Oncoletter haben folgende Firmen die Webseite vorübergehend/permanent und in wechselnden Zusammensetzungen (jährlich 4-6) unterstützt: Amgen, BMS, Celgene, GSK, Janssen-Cilag, Lilly, Merck, Mundipharma, Novartis, Pfizer, Roche, Servier.
Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren. Bei ausnahmsweise bezahlten Beiträgen oder Interviews (ausschliesslich on-label) wird der Sponsor im Text oder Abspann aufgeführt.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2022. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close